- Home
- About
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Supporting Organizations
The Curious Case Of Metabolic Dysfunction In Schizophrenia: Who’s Susceptible & Why?

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
The Curious Case Of Metabolic Dysfunction In Schizophrenia: Who’s Susceptible & Why?
A recent article1 published in World Psychiatry evaluated the mid and long term metabolic side effects of 31 antipsychotic drugs and confirmed that antipsychotic drugs differ in their propensity to induce metabolic side effects. Given that patients with schizophrenia often need lifelong treatment, careful consideration should be given when choosing an antipsychotic. Join a multidisciplinary panel including two metabolic-expert psychiatrists, a psychiatric nurse practitioner, and a licensed social worker highlighting:
- The heightened metabolic risk in drug-naïve individuals, the added risk when treating with antipsychotics
- What cardiometabolic parameters are important to measure (and why)
- What can be done to mitigate metabolic risks when considering risk/benefit
- Education regarding how the brain and body process sugar and implications for energy production will be discussed
- Evolution of metabolic guidelines and where we are headed
Reference:
- Burschinski A et al. World Psychiatry 2023; 22 :116-128

Christoph Correll, MD
Chair of the Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany. Professor of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA.
More

William Wirshing, MD
Clinical Professor of Psychiatry, Keck USC School of Medicine; and Medical Director of Exodus Recovery, Inc. in Los Angeles, CA
More

Michael Townsend, MA, LSW/LCSW
Deputy Chief Executive Officer, Gateway Counseling Center
More

Darcy Leon, PMHNP-BC
Psychiatric Nurse Practitioner
More

Laura Brennan, PhD (OPDC)
Medical Science Liaison
Christoph Correll, MD, William Wirshing, MD, Michael Townsend MA, LMSW and Darcy Leon, PMHNP-BC are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Laura Brennan, PhD is a paid employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)